Sino Biopharmaceutical’s LM-24C5 Receives NMPA Approval for Phase 2 Clinical Trials in CEACAM5-Positive Solid Tumors
Sino Biopharmaceutical Limited (HKG: 1177) announced that its independently developed LM-24C5 has received clinical trial...
Sino Biopharmaceutical
Sino Biopharmaceutical’s Rovadicitinib Granted Breakthrough Therapy Designation for Chronic Graft-versus-Host Disease
China-based Sino Biopharmaceutical Limited (HKG: 1177) announced that its self-developed JAK/ROCK dual small molecule inhibitor,...
Sino Biopharmaceutical’s TQC3302 Approved for COPD Maintenance Treatment Clinical Trials
Sino Biopharmaceutical Limited (HKG: 1177) announced that its independently developed Category 2.3 modified new drug,...
Sino Biopharmaceutical on Track to Receive $300M Milestone Payment for PD-1/VEGF Antibody Deal
China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that the out-licensing collaboration between its subsidiary...
CTTQ Doses First Patient in China for TQB6411 Phase I Clinical Trial
Subsidiary of China based Sino Biopharmaceutical Ltd (HKG: 1177) Jiangsu Chia Tai Tianqing Pharmaceutical Co.,...
Sino Biopharmaceutical Acquires Majority Stake in LaNova Medicines for USD 950.92 Million
China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced the acquisition of a 95.09% stake in Shanghai-based...
Jiangsu Chia Tai Tianqing’s Culmerciclib Receives NMPA Review for Expanded Breast Cancer Indication
Subsidiary of China based Sino Biopharmaceutical Ltd (HKG: 1177) Jiangsu Chia Tai Tianqing Pharmaceutical Co.,...
Jiangsu CTTQ’s TQB2102 Receives Breakthrough Therapy Designation for HER2+ Breast Cancer
Subsidiary of China based Sino Biopharmaceutical Ltd (HKG: 1177) Jiangsu Chia Tai Tianqing Pharmaceutical Co.,...
Sino Biopharmaceutical’s Recombinant Factor VIIa N01 Approved by NMPA for Hemophilia Treatment
China’s Sino Biopharmaceutical Ltd (HKG: 1177) announced that it has received marketing approval from the...
Sino Biopharmaceutical’s TDI01 Receives Breakthrough Therapy Designation for cGVHD Treatment
China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that its Class 1 drug TDI01 has been...
Sino Biopharmaceutical’s TQB2868 Approved for Phase III Trial in Metastatic Pancreatic Cancer
China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that it has received approval from the Center...
Sino Biopharmaceutical Gains CDE Approval for TQC3721 COPD Trial
China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that it has received approval from the Center...
Sino Biopharmaceutical Presents CAMPASS Phase III Results at ASCO 2025
China-based Sino Biopharmaceutical Ltd (HKG: 1177) presented the results of the Phase III CAMPASS study...
Sino Biopharmaceutical’s TQB2868 Shows Strong Results in Phase II Pancreatic Cancer Trial
China-based Sino Biopharmaceutical Ltd (HKG: 1177) presented data from its Phase II clinical trial (TQB2868-ALTN-II-01)...
Sino Biopharmaceutical Presents TQB2102 Phase I Results at ASCO 2025
China-based Sino Biopharmaceutical Ltd (HKG: 1177) presented preliminary results from a Phase I clinical study...
Sino Biopharmaceutical’s QP001 (Meloxicam) Approved by NMPA and FDA for Postoperative Pain
China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that its Category 2.2 drug QP001 (meloxicam) has...
Sino Biopharmaceutical and JD Healthcare Forge Comprehensive Strategic Partnership
China-based Sino Biopharmaceutical Ltd (HKG: 1177) and JD Healthcare, a unit of China’s e-commerce giant...
Hengrui Pharmaceuticals Gains NMPA Clearance for Phase II Study of HRS-7058 in Solid Tumors
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced clearance from the National Medical...
Sino Biopharma’s TQB3019 Gains NMPA Approval for Hematological Malignancies
China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that it has received clinical approval from the...
Sino Biopharmaceutical’s TQB2101 Receives NMPA Approval for Phase I Trial in Advanced Malignancies
China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that it has received approval from the National...